Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TriMixDC-MEL Adjuvant Therapy in Stage III/IV Melanoma
NCT01676779Phase 2Completed
- Sponsor
- UZ Brussel
- Start
- Oct 2012
- Primary completion
- Sep 2015
- Modality
- Prophylactic Vaccines, Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in melanoma comparing TriMixDC-MEL with Observation (2 arms). Primary endpoint: 1-year disease free survival percentage. Started Oct 2012; status: completed.
02
Drugs
TriMix-DC
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01676779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01676779.